Pulmatrix, Inc. (NASDAQ:PULM) Short Interest Update

Pulmatrix, Inc. (NASDAQ:PULM) was the recipient of a large decrease in short interest in July. As of July 15th, there was short interest totaling 27,481 shares, a decrease of 69.9% from the June 30th total of 91,267 shares. Approximately 0.8% of the company’s stock are sold short. Based on an average trading volume of 29,455 shares, the short-interest ratio is currently 0.9 days.

Pulmatrix Stock Performance

Shares of Pulmatrix stock traded down $0.03 during midday trading on Tuesday, reaching $1.70. 6,422 shares of the company’s stock traded hands, compared to its average volume of 45,561. Pulmatrix has a 52 week low of $1.16 and a 52 week high of $5.76. The company’s 50 day simple moving average is $1.53 and its 200 day simple moving average is $1.84. The company has a market cap of $6.21 million, a price-to-earnings ratio of -1.38 and a beta of 1.90.

Pulmatrix (NASDAQ:PULM) last posted its earnings results on Friday, May 15th. The biotechnology company reported ($0.32) earnings per share for the quarter.

Institutional Trading of Pulmatrix

A hedge fund recently bought a new position in Pulmatrix stock. Dimensional Fund Advisors LP acquired a new stake in Pulmatrix, Inc. (NASDAQ:PULM) in the 3rd quarter, according to the company in its most recent filing with the SEC. The fund acquired 10,780 shares of the biotechnology company’s stock, valued at approximately $52,000. Dimensional Fund Advisors LP owned about 0.30% of Pulmatrix as of its most recent filing with the SEC. Hedge funds and other institutional investors own 11.84% of the company’s stock.

Analyst Ratings Changes

Separately, Weiss Ratings cut shares of Pulmatrix from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, July 15th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Sell”.

About Pulmatrix

Pulmatrix, Inc is a clinical-stage biopharmaceutical company dedicated to developing inhaled therapies for patients suffering from respiratory diseases. The company’s proprietary iSPERSE® dry-powder formulation platform produces fine microparticles optimized for deep-lung delivery, rapid absorption and consistent dosing, addressing challenges often encountered with traditional inhalation approaches.

Among Pulmatrix’s lead programs is PUR1900, an inhaled therapy designed to treat pulmonary fungal infections such as allergic bronchopulmonary aspergillosis (ABPA).